R Garg, C Hussey, S Ibrahim. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Anti-Obesity Agents/adverse effectsAnti-Obesity Agents/therapeutic useDiabetes Mellitus, Type 2/drug therapyDrug Therapy, CombinationEnzyme Inhibitors/adverse effectsEnzyme Inhibitors/therapeutic useFemaleHumansLactones/adverse effectsLactones/therapeutic useMiddle AgedOrlistatPancreatitis/chemically inducedPyrazines/adverse effectsPyrazines/therapeutic useSitagliptin PhosphateTreatment OutcomeTriazoles/adverse effectsTriazoles/therapeutic use
Substances: See more » Anti-Obesity AgentsEnzyme InhibitorsLactonesPyrazinesTriazolesOrlistatSitagliptin Phosphate
Year: 2010 PMID: 20536524 DOI: 10.1111/j.1464-5491.2010.02950.x
Source DB: PubMed Journal: Diabet Med ISSN: 0742-3071 Impact factor: 4.359